By Deena Beasley Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite ...

Dec 12 (Reuters) - Bitcoin hoarding giant Strategy clung to its place in the Nasdaq 100 on Friday, continuing its year-long ...

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...

Biogen (BIIB) stock slips as HSBC downgrades to a Sell equivalent rating as part of an analysis that included an upgrade on ...

Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift ...

Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...

If you have been wondering whether Biogen's recent share price makes it a bargain or a value trap, you are not alone. This article is designed to help you cut through the noise and focus on what the ...

Strategy stock maintains Nasdaq 100 inclusion after rebalancing while MSCI reviews digital asset treasury companies. Decision ...

Zurzuvae was generally well-tolerated, with the most common side effects being sedation, somnolence and dizziness.

Bitcoin giant Strategy kept its spot in the Nasdaq 100 on Friday, holding its year-long run inside the index while debate ...

Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of ...

Health Canada has approved zuranolone, sold under the brand name Zurzuvae, as the first oral treatment for moderate to severe ...